Synthesis of Nitrogen Mustard-Modified HDAC Inhibitors for Enhanced Cancer Treatment
Poster Number
14C
Faculty Mentor Name
Qinliang Zhao
Format
Poster Presentation
Research or Creativity Area
Pharmacy
Abstract
Histone deacetylase (HDAC) inhibitors are an established class of anticancer agents known for their ability to regulate gene expression and promote apoptosis in cancer cells. However, many existing HDAC inhibitors face limitations such as low selectivity and reduced therapeutic effectiveness. To overcome these challenges, this project focuses on developing novel compounds that combine the HDAC inhibitory function of existing ligands with the DNA-targeting properties of nitrogen mustard derivatives. Two precursors previously synthesized in our lab serve as the foundation for this design. One precursor was chemically modified to form a nitrogen mustard derivative, which exhibits independent anticancer potential and can also act as a reactive intermediate for further hybrid molecule formation. The combination of the nitrogen mustard derivative with the second precursor aims to produce a dual-function compound capable of simultaneously disrupting DNA replication and inhibiting HDAC activity, thereby enhancing overall anticancer efficacy. Structural design and synthesis are guided by rational drug design principles, with subsequent characterization and evaluation planned to assess stability and potential biological activity. While this research is ongoing, it highlights the promising role of hybrid molecule development in creating more potent and selective cancer treatments that integrate both epigenetic and DNA-targeting mechanisms.
Location
University of the Pacific, DeRosa University Center
Start Date
24-4-2026 11:00 AM
End Date
24-4-2026 2:00 PM
Synthesis of Nitrogen Mustard-Modified HDAC Inhibitors for Enhanced Cancer Treatment
University of the Pacific, DeRosa University Center
Histone deacetylase (HDAC) inhibitors are an established class of anticancer agents known for their ability to regulate gene expression and promote apoptosis in cancer cells. However, many existing HDAC inhibitors face limitations such as low selectivity and reduced therapeutic effectiveness. To overcome these challenges, this project focuses on developing novel compounds that combine the HDAC inhibitory function of existing ligands with the DNA-targeting properties of nitrogen mustard derivatives. Two precursors previously synthesized in our lab serve as the foundation for this design. One precursor was chemically modified to form a nitrogen mustard derivative, which exhibits independent anticancer potential and can also act as a reactive intermediate for further hybrid molecule formation. The combination of the nitrogen mustard derivative with the second precursor aims to produce a dual-function compound capable of simultaneously disrupting DNA replication and inhibiting HDAC activity, thereby enhancing overall anticancer efficacy. Structural design and synthesis are guided by rational drug design principles, with subsequent characterization and evaluation planned to assess stability and potential biological activity. While this research is ongoing, it highlights the promising role of hybrid molecule development in creating more potent and selective cancer treatments that integrate both epigenetic and DNA-targeting mechanisms.
